Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Int J Mol Sci. 2023 Aug 7;24(15):12513. doi: 10.3390/ijms241512513.
Alzheimer's disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using microdosing, psychedelic drugs may prove to help combat this devastating disease by eliciting psychiatric benefits via acting through various mechanisms of action such as serotonin and dopamine pathways. Herein, we review the studied benefits of a few psychedelic compounds that may show promise in treating AD and attenuating its related depressive symptoms. We used the listed keywords to search through PubMed for relevant preclinical, clinical research, and review articles. The putative mechanism of action (MOA) for psychedelics is that they act mainly as serotonin receptor agonists and induce potential beneficial effects for treating AD and related depression.
阿尔茨海默病（AD）是最常见的老年痴呆症形式，随着人口老龄化，它将给社会和医疗保健带来更大的负担。由于针对该疾病症状缓解的治疗方法选择有限，且其病因病理尚不明确，因此迫切需要对 AD 进行更多的研究。致幻剂可针对 AD 相关的心理病理学和症状（如抑郁）发挥作用。通过微剂量使用，致幻剂可能通过通过 5-羟色胺和多巴胺等各种作用机制发挥作用，从而为治疗这种破坏性疾病提供帮助。本文综述了几种致幻化合物的研究益处，这些化合物可能在治疗 AD 和减轻其相关抑郁症状方面有一定的应用前景。我们使用列出的关键词在 PubMed 上搜索了相关的临床前、临床研究和综述文章。致幻剂的假定作用机制（MOA）是它们主要作为 5-羟色胺受体激动剂发挥作用，并诱导出治疗 AD 和相关抑郁的潜在有益效果。
